Royal Caribbean Expands Beyond Cruises With $3 Billion Sandals Partnership
The deal widens its vacation mix but drew a cautious market reaction.
Already have an account? Sign in.
The deal widens its vacation mix but drew a cautious market reaction.
Roche-Ionis sefaxersen beat placebo on proteinuria at week 37 in IgAN Phase 3. Monthly shot enters crowded market vs Novartis Fabhalta.
Doctors see 35%–40% U.S. share; peak sales estimate raised to about $400 million.
Investors sold CGNX on valuation and cash spend.